David Green Named CFO at Seastar Medical

SeaStar Medical Holding Corporation has appointed healthcare industry veteran David A. Green as chief financial officer (CFO). Interim CFO Caryl Baron will continue with the company as vice president of Finance.
 
“We welcome David to our executive team at this critical time as we prepare for our first commercial launch for the Selected Cytopheretic Device Pediatric (SCD-PED) later this quarter,” SeaStar Medical CEO Eric Schlorff said. “David’s extensive financial experience at public medical device and therapeutics companies will be highly valuable as we work to bring our groundbreaking solutions to those with devastating hyperinflammation. Importantly, David shares our commitment to improving patient outcomes and saving lives. On behalf of the entire SeaStar Medical team, I extend our thanks to Caryl for stepping into the CFO position on an interim basis during our transition to public company status. We look forward to her continued service to our company.”
 
Green has more than 25 years of financial experience primarily in the healthcare sector. He previously served as Interim CFO of Prolacta Bioscience, a private company providing specialized nutrition products to critically ill premature infants, where he led efforts to pursue an initial public offering. Before Prolacta, he was executive vice president and CFO of Aytu BioPharma, a publicly traded specialty pharmaceutical and medical device company marketing prescription and over-the-counter products. In this position, he completed multiple financing transactions and was instrumental in the company’s M&A activities. Earlier, Green was chief accounting officer at Intarcia Therapeutics, a commercial-stage biopharmaceutical company; CFO of Catheter Connections, a commercial-stage medical device company acquired by Merit Medical; and CFO of Specialized Health Products International, a publicly traded medical device company acquired by C.R. Bard. Since 2014 Green has provided strategic financial consulting services to public and private healthcare companies.
 
Earlier in his career, Green was managing director at Duff & Phelps, a global investment banking and corporate finance advisory firm, and as a founding member of Ernst & Young’s Palo Alto Center for Strategic Transactions, where he advised clients on using strategic transactions to accelerate growth. Green earned a bachelor of science degree from the State University of New York and an MBA from the University of Rochester. He is a certified public accountant in Illinois.

“SeaStar Medical’s cell-directed extracorporeal therapy holds potential in multiple high-value indications to stop the threat of a dysregulated inflammatory response that can cause organ damage and even death, while also reducing healthcare system costs,” Green stated. “I’m excited to join this focused and highly motivated team.”
 
SeaStar Medical is a medical technology company that is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.